Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 8/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 5/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4999188 | 0.98 | KDM4E (0.43) | KDM4EPOLBEPHX2NPSR1DPP4 | |
| SCHEMBL4999703 | 0.96 | KDM4E (0.38) | KDM4EPOLBEPHX2NPSR1DPP4 | |
| SCHEMBL756137 | 0.83 | EPHX2 (0.40) | KDM4EEPHX2NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL754816 | 0.81 | EPHX2 (0.42) | KDM4EPOLBEPHX2NPSR1ALDH1A1 | |
| SCHEMBL8266907 | 0.81 | KDM4E (0.42) | KDM4EPOLBDPP4ALDH1A1FAP | |
| SCHEMBL8266594 | 0.79 | KDM4E (0.44) | KDM4EPOLBDPP4ALDH1A1FAP | |
| SCHEMBL8266999 | 0.77 | DPP4 (0.40) | KDM4EPOLBDPP4FAPDPP7 | |
| SCHEMBL8294299 | 0.75 | ALDH1A1 (0.50) | KDM4EPOLBNPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL751989 | 0.75 | EPHX2 (0.32) | KDM4EEPHX2ALDH1A1 | |
| SCHEMBL1977433 | 0.75 | EPHX2 (0.59) | KDM4EPOLBEPHX2NPSR1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-7205330-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1730165-A1 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | SCHERING CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050267043-A1 | Novel inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION | 2005-12-01 | — | — | US | disclosed |
| WO-2005085275-A1 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | HAVCR2, RNASE1, SERPINB1 | KDM4E 966/4885POLB 3834/4885EPHX2 2137/4885 |
| US-20050267043-A1 | Novel inhibitors of hepatitis C virus NS3 protease | HAVCR2, RNASE1, SERPINB1 | KDM4E 966/4885POLB 3834/4885EPHX2 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.